^
Association details:
| Biomarker: | EGFR mutation + EGFR T790M |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters
Published date:
02/21/2022
Excerpt:
Consecutive metastatic EGFR-mutant NSCLC patients receiving first-line EGFR-TKIs from October 2010 to March 2020....Nine of the 17 patients with de novo T790M mutation received Osimertinib, whose overall survival tended to be longer than the remaining 8 patients without Osimertinib treatment (p = 0.08)…. Osimertinib was associated with promising efficacy in patients with de novo T790M mutation, which warranted further validation.
DOI:
10.1186/s12885-022-09245-5
Source:
Title:
ctDNA analysis reveals different molecular patterns upon disease progression in patients treated with osimertinib
Published date:
03/13/2020
Excerpt:
Likewise, re-emergence of the original EGFR mutation, alone or together with the p.T790M mutation was significantly associated with shorter PFS (HR: 8.8, 95% CI: 1.1-70.7 and HR: 5.9, 95% CI: 1.2-27.9, respectively)
DOI:
10.21037/tlcr.2020.04.01
